The combination of CJC-1295 (with DAC) and Ipamorelin is a widely studied peptide blend in endocrine and regenerative research for its potential to enhance growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels through two distinct yet synergistic mechanisms. CJC-1295, a long-acting GHRH analog, increases GH production over time, while Ipamorelin—a selective ghrelin receptor agonist—triggers rapid GH release with minimal impact on other hormonal pathways, such as cortisol or prolactin. This makes the blend especially attractive for muscle recovery, fat metabolism, anti-aging, and neuroendocrine studies.
CJC-1295 acts on GHRH receptors in the pituitary gland, stimulating sustained GH release by mimicking endogenous GHRH. Its Drug Affinity Complex (DAC) modification binds the molecule to albumin, extending its half-life to approximately 5.8 to 8.1 days, allowing for weekly or biweekly dosing in research protocols.
Ipamorelin, on the other hand, is a highly selective agonist of the GHS-R1a (ghrelin receptor). It induces acute GH pulses without significantly affecting cortisol, ACTH, or prolactin—unlike older GHRPs such as GHRP-6 or Hexarelin. Ipamorelin’s selective profile makes it suitable for long-term studies with minimal off-target endocrine activation.
Together, the blend:
Provides continuous GH production via CJC-1295
Induces fast GH release via Ipamorelin
Results in a stable, elevated IGF-1 environment supporting anabolic and metabolic processes
Preclinical Studies:
In animal models, the CJC-1295 and Ipamorelin combination has demonstrated:
Synergistic increases in GH and IGF-1, supporting improved muscle hypertrophy, fat reduction, and connective tissue repair
The blend has also been associated with enhanced collagen synthesis, mitochondrial function, and immune modulation in aging and injury models
Ipamorelin has been noted for its neuroprotective potential and favorable cardiovascular profile, expanding its relevance in age-related and neuroendocrine research.
Intended Use:
The information provided on this site is intended exclusively for educational and research purposes and should not be interpreted as medical guidance.
Research compounds, including CJC-1295 and Ipamorelin, are designed solely for laboratory investigation by qualified professionals and are not intended for human use or consumption.
The statements presented here have not been evaluated by the U.S. Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease.
Choosing a selection results in a full page refresh.
